Cargando…
VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy—A Message from COMET, a French Unicancer Multicentric Study
The prospective multicenter COMET trial followed a cohort of 306 consecutive metastatic breast cancer patients receiving bevacizumab and paclitaxel as first-line chemotherapy. This study was intended to identify and validate reliable biomarkers to better predict bevacizumab treatment outcomes and al...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7700430/ https://www.ncbi.nlm.nih.gov/pubmed/33238394 http://dx.doi.org/10.3390/ph13110414 |
_version_ | 1783616278404005888 |
---|---|
author | Gal, Jocelyn Milano, Gérard Brest, Patrick Ebran, Nathalie Gilhodes, Julia Llorca, Laurence Dubot, Coraline Romieu, Gilles Desmoulins, Isabelle Brain, Etienne Goncalves, Anthony Ferrero, Jean-Marc Cottu, Paul-Henri Debled, Marc Tredan, Olivier Chamorey, Emmanuel Merlano, Marco Carlo Lemonnier, Jérôme Etienne-Grimaldi, Marie-Christine Pierga, Jean-Yves |
author_facet | Gal, Jocelyn Milano, Gérard Brest, Patrick Ebran, Nathalie Gilhodes, Julia Llorca, Laurence Dubot, Coraline Romieu, Gilles Desmoulins, Isabelle Brain, Etienne Goncalves, Anthony Ferrero, Jean-Marc Cottu, Paul-Henri Debled, Marc Tredan, Olivier Chamorey, Emmanuel Merlano, Marco Carlo Lemonnier, Jérôme Etienne-Grimaldi, Marie-Christine Pierga, Jean-Yves |
author_sort | Gal, Jocelyn |
collection | PubMed |
description | The prospective multicenter COMET trial followed a cohort of 306 consecutive metastatic breast cancer patients receiving bevacizumab and paclitaxel as first-line chemotherapy. This study was intended to identify and validate reliable biomarkers to better predict bevacizumab treatment outcomes and allow for a more personalized use of this antiangiogenic agent. To that end, we aimed to establish risk scores for survival prognosis dichotomization based on classic clinico-pathological criteria combined or not with single nucleotide polymorphisms (SNPs). The genomic DNA of 306 patients was extracted and a panel of 13 SNPs, covering seven genes previously documented to be potentially involved in drug response, were analyzed by means of high-throughput genotyping. In receiver operating characteristic (ROC) analyses, the hazard model based on a triple-negative cancer phenotype variable, combined with specific SNPs in VEGFA (rs833061), VEGFR1 (rs9582036) and VEGFR2 (rs1870377), had the highest predictive value. The overall survival hazard ratio of patients assigned to the poor prognosis group based on this model was 3.21 (95% CI (2.33–4.42); p < 0.001). We propose that combining this pharmacogenetic approach with classical clinico-pathological characteristics could markedly improve clinical decision-making for breast cancer patients receiving bevacizumab-based therapy. |
format | Online Article Text |
id | pubmed-7700430 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77004302020-11-30 VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy—A Message from COMET, a French Unicancer Multicentric Study Gal, Jocelyn Milano, Gérard Brest, Patrick Ebran, Nathalie Gilhodes, Julia Llorca, Laurence Dubot, Coraline Romieu, Gilles Desmoulins, Isabelle Brain, Etienne Goncalves, Anthony Ferrero, Jean-Marc Cottu, Paul-Henri Debled, Marc Tredan, Olivier Chamorey, Emmanuel Merlano, Marco Carlo Lemonnier, Jérôme Etienne-Grimaldi, Marie-Christine Pierga, Jean-Yves Pharmaceuticals (Basel) Article The prospective multicenter COMET trial followed a cohort of 306 consecutive metastatic breast cancer patients receiving bevacizumab and paclitaxel as first-line chemotherapy. This study was intended to identify and validate reliable biomarkers to better predict bevacizumab treatment outcomes and allow for a more personalized use of this antiangiogenic agent. To that end, we aimed to establish risk scores for survival prognosis dichotomization based on classic clinico-pathological criteria combined or not with single nucleotide polymorphisms (SNPs). The genomic DNA of 306 patients was extracted and a panel of 13 SNPs, covering seven genes previously documented to be potentially involved in drug response, were analyzed by means of high-throughput genotyping. In receiver operating characteristic (ROC) analyses, the hazard model based on a triple-negative cancer phenotype variable, combined with specific SNPs in VEGFA (rs833061), VEGFR1 (rs9582036) and VEGFR2 (rs1870377), had the highest predictive value. The overall survival hazard ratio of patients assigned to the poor prognosis group based on this model was 3.21 (95% CI (2.33–4.42); p < 0.001). We propose that combining this pharmacogenetic approach with classical clinico-pathological characteristics could markedly improve clinical decision-making for breast cancer patients receiving bevacizumab-based therapy. MDPI 2020-11-23 /pmc/articles/PMC7700430/ /pubmed/33238394 http://dx.doi.org/10.3390/ph13110414 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gal, Jocelyn Milano, Gérard Brest, Patrick Ebran, Nathalie Gilhodes, Julia Llorca, Laurence Dubot, Coraline Romieu, Gilles Desmoulins, Isabelle Brain, Etienne Goncalves, Anthony Ferrero, Jean-Marc Cottu, Paul-Henri Debled, Marc Tredan, Olivier Chamorey, Emmanuel Merlano, Marco Carlo Lemonnier, Jérôme Etienne-Grimaldi, Marie-Christine Pierga, Jean-Yves VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy—A Message from COMET, a French Unicancer Multicentric Study |
title | VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy—A Message from COMET, a French Unicancer Multicentric Study |
title_full | VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy—A Message from COMET, a French Unicancer Multicentric Study |
title_fullStr | VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy—A Message from COMET, a French Unicancer Multicentric Study |
title_full_unstemmed | VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy—A Message from COMET, a French Unicancer Multicentric Study |
title_short | VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy—A Message from COMET, a French Unicancer Multicentric Study |
title_sort | vegf-related germinal polymorphisms may identify a subgroup of breast cancer patients with favorable outcome under bevacizumab-based therapy—a message from comet, a french unicancer multicentric study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7700430/ https://www.ncbi.nlm.nih.gov/pubmed/33238394 http://dx.doi.org/10.3390/ph13110414 |
work_keys_str_mv | AT galjocelyn vegfrelatedgerminalpolymorphismsmayidentifyasubgroupofbreastcancerpatientswithfavorableoutcomeunderbevacizumabbasedtherapyamessagefromcometafrenchunicancermulticentricstudy AT milanogerard vegfrelatedgerminalpolymorphismsmayidentifyasubgroupofbreastcancerpatientswithfavorableoutcomeunderbevacizumabbasedtherapyamessagefromcometafrenchunicancermulticentricstudy AT brestpatrick vegfrelatedgerminalpolymorphismsmayidentifyasubgroupofbreastcancerpatientswithfavorableoutcomeunderbevacizumabbasedtherapyamessagefromcometafrenchunicancermulticentricstudy AT ebrannathalie vegfrelatedgerminalpolymorphismsmayidentifyasubgroupofbreastcancerpatientswithfavorableoutcomeunderbevacizumabbasedtherapyamessagefromcometafrenchunicancermulticentricstudy AT gilhodesjulia vegfrelatedgerminalpolymorphismsmayidentifyasubgroupofbreastcancerpatientswithfavorableoutcomeunderbevacizumabbasedtherapyamessagefromcometafrenchunicancermulticentricstudy AT llorcalaurence vegfrelatedgerminalpolymorphismsmayidentifyasubgroupofbreastcancerpatientswithfavorableoutcomeunderbevacizumabbasedtherapyamessagefromcometafrenchunicancermulticentricstudy AT dubotcoraline vegfrelatedgerminalpolymorphismsmayidentifyasubgroupofbreastcancerpatientswithfavorableoutcomeunderbevacizumabbasedtherapyamessagefromcometafrenchunicancermulticentricstudy AT romieugilles vegfrelatedgerminalpolymorphismsmayidentifyasubgroupofbreastcancerpatientswithfavorableoutcomeunderbevacizumabbasedtherapyamessagefromcometafrenchunicancermulticentricstudy AT desmoulinsisabelle vegfrelatedgerminalpolymorphismsmayidentifyasubgroupofbreastcancerpatientswithfavorableoutcomeunderbevacizumabbasedtherapyamessagefromcometafrenchunicancermulticentricstudy AT brainetienne vegfrelatedgerminalpolymorphismsmayidentifyasubgroupofbreastcancerpatientswithfavorableoutcomeunderbevacizumabbasedtherapyamessagefromcometafrenchunicancermulticentricstudy AT goncalvesanthony vegfrelatedgerminalpolymorphismsmayidentifyasubgroupofbreastcancerpatientswithfavorableoutcomeunderbevacizumabbasedtherapyamessagefromcometafrenchunicancermulticentricstudy AT ferrerojeanmarc vegfrelatedgerminalpolymorphismsmayidentifyasubgroupofbreastcancerpatientswithfavorableoutcomeunderbevacizumabbasedtherapyamessagefromcometafrenchunicancermulticentricstudy AT cottupaulhenri vegfrelatedgerminalpolymorphismsmayidentifyasubgroupofbreastcancerpatientswithfavorableoutcomeunderbevacizumabbasedtherapyamessagefromcometafrenchunicancermulticentricstudy AT debledmarc vegfrelatedgerminalpolymorphismsmayidentifyasubgroupofbreastcancerpatientswithfavorableoutcomeunderbevacizumabbasedtherapyamessagefromcometafrenchunicancermulticentricstudy AT tredanolivier vegfrelatedgerminalpolymorphismsmayidentifyasubgroupofbreastcancerpatientswithfavorableoutcomeunderbevacizumabbasedtherapyamessagefromcometafrenchunicancermulticentricstudy AT chamoreyemmanuel vegfrelatedgerminalpolymorphismsmayidentifyasubgroupofbreastcancerpatientswithfavorableoutcomeunderbevacizumabbasedtherapyamessagefromcometafrenchunicancermulticentricstudy AT merlanomarcocarlo vegfrelatedgerminalpolymorphismsmayidentifyasubgroupofbreastcancerpatientswithfavorableoutcomeunderbevacizumabbasedtherapyamessagefromcometafrenchunicancermulticentricstudy AT lemonnierjerome vegfrelatedgerminalpolymorphismsmayidentifyasubgroupofbreastcancerpatientswithfavorableoutcomeunderbevacizumabbasedtherapyamessagefromcometafrenchunicancermulticentricstudy AT etiennegrimaldimariechristine vegfrelatedgerminalpolymorphismsmayidentifyasubgroupofbreastcancerpatientswithfavorableoutcomeunderbevacizumabbasedtherapyamessagefromcometafrenchunicancermulticentricstudy AT piergajeanyves vegfrelatedgerminalpolymorphismsmayidentifyasubgroupofbreastcancerpatientswithfavorableoutcomeunderbevacizumabbasedtherapyamessagefromcometafrenchunicancermulticentricstudy |